Table 5.
Adverse Events (Treated Set)
n (%) | Child‐Pugh A (n = 8) | Child‐Pugh B (n = 8) | Healthy (n = 17) |
---|---|---|---|
Subjects with any AE | 0 | 3 (37.5) | 3 (17.6) |
Headache | 0 | 0 | 1 (5.9) |
Diarrhea | 0 | 1 (12.5) | 0 |
Nausea | 0 | 1 (12.5) | 2 (11.8) |
Vomiting | 0 | 0 | 1 (5.9) |
Pruritus | 0 | 1 (12.5) | 0 |
Skin irritation | 0 | 1 (12.5) | 0 |
Adverse events (AEs) were reported according to MedDRA version 17.1. AEs with onset between administration of trial medication and the end of the 28‐day posttreatment follow‐up period are shown.